If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

Emma P. Deloughery, Vinay Prasad

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalJournal of General Internal Medicine
StateAccepted/In press - Jun 4 2018

ASJC Scopus subject areas

  • Internal Medicine

Cite this